The overall theme of this competitive renewal application is to characterize immune responses induced upon gene transfer by adeno-associated virus (AAV) vectors and to devise avenues to circumvent effector Immune responses that impede sustained gene transfer. In its 1(r)'objective, the program will analyze T cell responses to the capsid antigens of AAV vectors pseudotyped with capsids of different serotypes or with genetically modified capsids using in vitro systems, experimental animals and samples from human subjects to assess functionality of T cells induced by natural infections or AAV gene transfer and to determine the longevity of T cell responses to the latter. Avenues to circumvent destructive T cell responses to AAV gene transfer including capsid modifications and pharmacological interventions will be explored. In its 2"""""""""""""""" objective, the program will analyze T cell responses to the transgene product of AAV vectors with focus on double-stranded AAV vectors that according to preliminary data of the program elicit more potent innate and adaptive immune responses than single-stranded AAV vectors. In its 3""""""""^ objective, the program will explore the use of regulatory T cells (Tregs) to suppress destructive immune responses against AAV capsid or therapeutic proteins such as clotting factors to prevent a primary response to gene transfer or to down-regulate an existing response to AAV-mediated gene transfer or protein therapy. The program is divided into 3 Projects supported by 2 Cores. Project 1 (KA High): Immune Responses to Capsid in AAV-Mediated Gene Transfer Project 2 (HC ErtI): T Cells to AAV and AAV-Encoded Transgene Products Project 3 (RW Herzog, C Terliorst): Pathways Towards Immune Tolerance to Coagulation Factors Core A (HC ErtI): Administrative Core Core B (S Zliou): Vector Core

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL078810-08
Application #
8282768
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Program Officer
Link, Rebecca P
Project Start
2004-12-01
Project End
2015-06-30
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
8
Fiscal Year
2012
Total Cost
$1,702,657
Indirect Cost
$182,033
Name
Wistar Institute
Department
Type
DUNS #
075524595
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
High, Katherine A; Anguela, Xavier M (2016) Adeno-associated viral vectors for the treatment of hemophilia. Hum Mol Genet 25:R36-41
Vercauteren, Koen; Hoffman, Brad E; Zolotukhin, Irene et al. (2016) Superior In vivo Transduction of Human Hepatocytes Using Engineered AAV3 Capsid. Mol Ther 24:1042-1049
Wang, Xiaomei; Terhorst, Cox; Herzog, Roland W (2016) In vivo induction of regulatory T cells for immune tolerance in hemophilia. Cell Immunol 301:18-29
Sharma, Rajiv; Anguela, Xavier M; Doyon, Yannick et al. (2015) In vivo genome editing of the albumin locus as a platform for protein replacement therapy. Blood 126:1777-84
Biswas, Moanaro; Terhorst, Cox; Herzog, Roland W (2015) Treg: tolerance vs immunity. Oncotarget 6:19956-7
Biswas, Moanaro; Sarkar, Debalina; Kumar, Sandeep R P et al. (2015) Synergy between rapamycin and FLT3 ligand enhances plasmacytoid dendritic cell-dependent induction of CD4+CD25+FoxP3+ Treg. Blood 125:2937-47
Rogers, Geoffrey L; Suzuki, Masataka; Zolotukhin, Irene et al. (2015) Unique Roles of TLR9- and MyD88-Dependent and -Independent Pathways in Adaptive Immune Responses to AAV-Mediated Gene Transfer. J Innate Immun 7:302-14
Rogers, Geoffrey L; Herzog, Roland W (2015) Gene therapy for hemophilia. Front Biosci (Landmark Ed) 20:556-603
Hui, Daniel J; Edmonson, Shyrie C; Podsakoff, Gregory M et al. (2015) AAV capsid CD8+ T-cell epitopes are highly conserved across AAV serotypes. Mol Ther Methods Clin Dev 2:15029
Wang, Xiaomei; Su, Jin; Sherman, Alexandra et al. (2015) Plant-based oral tolerance to hemophilia therapy employs a complex immune regulatory response including LAP+CD4+ T cells. Blood 125:2418-27

Showing the most recent 10 out of 74 publications